Since clinical development of these novel agents will occur in the ever-changing treatment landscape, this review will first provide an overview of the current prostate cancer treatment landscape, followed by a comprehensive literature review of drugs that either directly or indirectly target AR-Vs. The gene discussed is AR; the disease is prostate carcinoma.